LOGIN  |  REGISTER
Recursion

HEALWELL AI Announces Voting Results of 2024 Annual General Meeting of its Shareholders

June 25, 2024 | Last Trade: C$ 2.34 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare technology company focused on AI and data science for preventative care, is pleased to announce the voting results from its annual general meeting of the shareholders of the Company held on June 25, 2024 (the "Meeting"). Shareholders holding shares entitled to exercise approximately 77.61% of the votes attributable to all of HEALWELL's outstanding shares attended the Meeting in person or were represented by proxy.

All matters of business set out in the Company's management information circular dated May 23, 2024 (the "Circular") were passed at the Meeting, including:

  • Fixing the number of directors at five and electing management's five nominees to the board of directors.

  • Appointing PricewaterhouseCoopers LLP ("PwC") as auditor of the Company.

Additional details on the voting results are set out below. For more information on the resolutions and the business of the Meeting, readers should refer to the Circular, a copy of which is available under the Company's profile on SEDAR+ at www.sedarplus.com.

Election of Directors

304,378,958 votes, or approximately 100% of the votes cast at the Meeting, were cast in favour of the fixing the number of directors of the Company at five.

The details of the voting results for the election of each of the five director nominees are set out below:

NomineeVotes For% ForVotes Withheld% Withheld
Dr. Alexander Dobranowski303,187,91799.6121,181,0830.388
Kingsley Ward303,142,91999.5971,226,0810.403
Bashar Al-Rehany303,141,91999.5971,227,0810.403
Hamed Shahbazi303,142,91799.5971,226,0830.403
Erik Danudjaja303 ,187,91799.6121,181,0830.388

Appointment of Auditors

304,379,460 votes, or approximately 100% of the votes cast at the Meeting, were cast in favour of appointing PwC as the new external auditor of the Company. PwC was selected following a recommendation from the Company's Audit Committee after taking into consideration, among other things, PWC's qualifications, cost, staffing model, technology and independence, and succeeds the Company's former auditor, BDO Canada LLP ("BDO").

Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.

About HEALWELL AI

HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange (the "TSX") under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.

For more information:

Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
This email address is being protected from spambots. You need JavaScript enabled to view it.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Recursion

Stock Quote

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB